We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Exploring the Role of Adipocyte Fatty Acid Binding Protein in the Association of Obstructive Sleep Apnea and Metabolic Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01173432
Recruitment Status : Active, not recruiting
First Posted : August 2, 2010
Last Update Posted : October 31, 2017
Information provided by:
The University of Hong Kong

Brief Summary:
Adipocyte fatty acid binding protein (A-FABP) is a member of the FABP super family, is abundant in adipocytes and macrophages. Regulatory functions of A-FABP in lipid and glucose metabolism have been described, and it is suggested to play an important role in the pathogenesis of metabolic syndrome.We hypothesize that obstructive sleep apnea (OSA) may upregulate A-FABP production and thus causally contribute to metabolic dysfunction. Our group has recently demonstrated that A-FABP, expressed and secreted from adipocytes, is present in the blood stream .The levels of A-FABP correlated with various metabolic variates in the metabolic syndrome. Furthermore, we have obtained novel data in men with a range of sleep disordered breathing showed that the duration of oxygen desaturation correlated with circulating levels of A-FABP, independent of age and waist/body mass index. The current proposal aims to pursue this finding and further explore the role of A-FABP in the association of OSA and metabolic dysfunction.

Condition or disease Intervention/treatment
Obstructive Sleep Apnea Insulin Resistance Metabolic Syndrome Inflammation Device: continuous positive airway pressure

Detailed Description:

We hypothesize that there are changes in circulating A-FABP level which can be mitigated by effective treatment of OSA.

The aim is to investigate the effect of CPAP treatment of OSA on circulating A-FABP, and the relationship of changes in serum A-FABP with changes in oxidative stress, inflammation and metabolic variates.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 95 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial of the Effect of Continuous Positive Airway Pressure on Adipocyte Fatty Acid Binding Protein and Other Metabolic Markers in Obstructive Sleep Apnea
Study Start Date : June 2008
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: continuous positive airway pressure
using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
Device: continuous positive airway pressure
an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
No Intervention: control
observation for the study period (4 weeks, no CPAP)

Primary Outcome Measures :
  1. adipocyte fatty acid binding protein [ Time Frame: changes over 4 weeks of CPAP treatment ]
    This will be done with human A-FABP ELISA reagent set (Biovendor Laboratory Medicine Inc., Czech Republic)

Secondary Outcome Measures :
  1. serum Insulin and glucose [ Time Frame: changes over 4 weeks of CPAP treatment ]
    Serum insulin will be determined with microparticle enzyme immunoassay on Abbott IMx system (Abbott, Abbott Park, IL). Plasma glucose will be measured by the glucose oxidase method on a Beckman autoanalyzer (Beckman Instruments, Bream, CA). The estimation of insulin resistance by the homeostasis model assessment method (HOMA-IR) will be calculated

  2. Lipids and lipoprotein [ Time Frame: changes over 4 weeks of CPAP treatment ]
    Plasma total cholesterol and triglyceride will be determined enzymatically on Hitachi 912 analyzer .

  3. serum advanced oxidation protein products AOPP [ Time Frame: changes over 4 weeks of CPAP treatment ]
    measurement of AOPP using a microplate reader by spectrophotometric detection method

  4. serum Total plasma 8-isoprostane [ Time Frame: changes over 4 weeks of CPAP treatment ]
    measured by a specific enzyme immunoassay kit

  5. serum inflammatory markers [ Time Frame: changes over 4 weeks of CPAP treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects between 18 - 65 years old
  • Able to understand and give informed written consent

Exclusion Criteria:

  • BMI > 35 kg/m2
  • known diabetes mellitus or hyperlipidemia on treatment
  • known cardiovascular disease except hypertension stable on treatment
  • unstable medical illness
  • need for starting treatment for OSA or other medical conditions immediately

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01173432

Hong Kong
The University of Hong Kong
Hong Kong, Hong Kong, 852
Sponsors and Collaborators
The University of Hong Kong
Principal Investigator: Mary SM Ip, MD The University of Hong Kong, Queen Mary Hospital

Responsible Party: Professor Mary SM Ip, The University of Hong Kong, Queen Mary Hospital
ClinicalTrials.gov Identifier: NCT01173432     History of Changes
Other Study ID Numbers: UW07-178
HKCTR-770 ( Registry Identifier: Clinical trial centre, The University of Hong Kong )
First Posted: August 2, 2010    Key Record Dates
Last Update Posted: October 31, 2017
Last Verified: October 2017

Keywords provided by The University of Hong Kong:
obstructive sleep apnea
metabolic dysfunction
metabolic syndrome
adipocyte fatty acid binding protein

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Metabolic Syndrome X
Sleep Apnea, Obstructive
Insulin Resistance
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Glucose Metabolism Disorders
Metabolic Diseases